Epiomic Epidemiology Series: Hypertension Forecast in 19 Major Markets 2018–2028

July 2018 | 70 pages | ID: E157FC51542EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Hypertension in 19 Major Markets

Hypertension (high blood pressure) is a common condition in which the force of the blood against the artery walls is high enough that it may eventually cause serious health problems. These health problems include heart attack, stroke, chronic kidney disease and heart failure.

This report provides the current prevalent population for Hypertension across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Hypertension have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Hypertension include:

• Chronic heart failure
• Chronic kidney disease
• Myocardial infarction
• Ischaemic heart disease
• Stroke
• Diabetes
• Metabolic syndrome

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global Hypertension market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of Hypertension and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding on the impact of specific co-morbid conditions on the prevalent population of Hypertension patients.
• Identification of Hypertension patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of Hypertension patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR HYPERTENSION

FEATURES OF HYPERTENSION PATIENTS

COMORBIDITIES OF HYPERTENSION PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Classification of hypertension
Table 2. Prevalence of hypertension, total (000s)
Table 3. Prevalence of hypertension, males (000s)
Table 4. Prevalence of hypertension, females (000s)
Table 5. Patients with hypertension by control status, total (000s)
Table 6. Diagnosed/Aware hypertension patients, total (000s)
Table 7. Patients with hypertension by BMI status, total (000s)
Table 8. Patients with hypertension by kidney function, total (000s)
Table 9. Hypertension patients with diabetes, total (000s)
Table 10. Hypertension patients with chronic heart failure, total (000s)
Table 11. Hypertension patients with coronary artery disease, total (000s)
Table 12. Hypertension patients with peripheral artery disease, total (000s)
Table 13. Hypertension patients with dyslipidaemia, total (000s)
Table 14. Hypertension patients with elevated CRP, total (000s)
Table 15. Hypertension patients with metabolic syndrome, total (000s)
Table 16. Hypertension patients with retinopathy, total (000s)
Table 17. Hypertension patients with atrial fibrillation, total (000s)
Table 18. Abbreviations and acronyms used in the report
Table 19. USA prevalence of hypertension by 5-yr age cohort, males (000s)
Table 20. USA prevalence of hypertension by 5-yr age cohort, females (000s)
Table 21. Canada prevalence of hypertension by 5-yr age cohort, males (000s)
Table 22. Canada prevalence of hypertension by 5-yr age cohort, females (000s)
Table 23. France prevalence of hypertension by 5-yr age cohort, males (000s)
Table 24. France prevalence of hypertension by 5-yr age cohort, females (000s)
Table 25. Germany prevalence of hypertension by 5-yr age cohort, males (000s)
Table 26. Germany prevalence of hypertension by 5-yr age cohort, females (000s)
Table 27. Italy prevalence of hypertension by 5-yr age cohort, males (000s)
Table 28. Italy prevalence of hypertension by 5-yr age cohort, females (000s)
Table 29. Spain prevalence of hypertension by 5-yr age cohort, males (000s)
Table 30. Spain prevalence of hypertension by 5-yr age cohort, females (000s)
Table 31. UK prevalence of hypertension by 5-yr age cohort, males (000s)
Table 32. UK prevalence of hypertension by 5-yr age cohort, females (000s)
Table 33. Poland prevalence of hypertension by 5-yr age cohort, males (000s)
Table 34. Poland prevalence of hypertension by 5-yr age cohort, females (000s)
Table 35. Netherlands prevalence of hypertension by 5-yr age cohort, males (000s)
Table 36. Netherlands prevalence of hypertension by 5-yr age cohort, females (000s)
Table 37. Russia prevalence of hypertension by 5-yr age cohort, males (000s)
Table 38. Russia prevalence of hypertension by 5-yr age cohort, females (000s)
Table 39. Turkey prevalence of hypertension by 5-yr age cohort, males (000s)
Table 40. Turkey prevalence of hypertension by 5-yr age cohort, females (000s)
Table 41. Japan prevalence of hypertension by 5-yr age cohort, males (000s)
Table 42. Japan prevalence of hypertension by 5-yr age cohort, females (000s)
Table 43. China prevalence of hypertension by 5-yr age cohort, males (000s)
Table 44. China prevalence of hypertension by 5-yr age cohort, females (000s)
Table 45. South Korea prevalence of hypertension by 5-yr age cohort, males (000s)
Table 46. South Korea prevalence of hypertension by 5-yr age cohort, females (000s)
Table 47. India prevalence of hypertension by 5-yr age cohort, males (000s)
Table 48. India prevalence of hypertension by 5-yr age cohort, females (000s)
Table 49. Australia prevalence of hypertension by 5-yr age cohort, males (000s)
Table 50. Australia prevalence of hypertension by 5-yr age cohort, females (000s)
Table 51. Brazil prevalence of hypertension by 5-yr age cohort, males (000s)
Table 52. Brazil prevalence of hypertension by 5-yr age cohort, females (000s)
Table 53. Mexico prevalence of hypertension by 5-yr age cohort, males (000s)
Table 54. Mexico prevalence of hypertension by 5-yr age cohort, females (000s)
Table 55. Argentina prevalence of hypertension by 5-yr age cohort, males (000s)
Table 56. Argentina prevalence of hypertension by 5-yr age cohort, females (000s)